Weissferdt Annikka, Phan Alexandria, Suster Saul, Moran Cesar A
Departments of *Pathology †GI Medical Oncology, MD Anderson Cancer Center, Houston, TX ‡Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.
Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):24-30. doi: 10.1097/PAI.0b013e31828a96cf.
Adrenocortical carcinomas (ACC) are uncommon tumors of the adrenal cortex that are known to follow an aggressive clinical course. The distinction of these tumors from other neoplasms may sometimes prove difficult due to overlapping clinical, morphologic, and even immunophenotypical features. To this end, we performed a comprehensive immunohistochemical analysis using traditional and novel markers in 40 cases of ACC. An immunohistochemical panel consisting of 10 traditional and novel antibodies was applied to whole tissue sections of ACC including high-molecular weight cytokeratin (HMWCK), low-molecular weight cytokeratin (CAM5.2), inhibin-α, melan A, chromogranin A, synaptophysin, calretinin, steroid receptor coactivator-1 (SRC-1), Pax8, and Ki67. The percentage of positive tumor cells as well as the intensity of staining were evaluated and scored; for Ki67 the percentage of positive tumor cells was recorded. Positive staining was observed for SRC-1 (39/40; 97.5%), inhibin-α (37/40; 92.5%), calretinin (32/40; 80%), synaptophysin (29/40; 72.5%), melan A (26/40; 65%), and CAM5.2 (9/40; 22.5%). Rare cases showed positivity for chromogranin A (2/40; 5%) and Pax8 (1/40; 2.5%). None of the cases showed any reactivity with HMWCK. The Ki67 index ranged from <5% to 20%. We conclude that there is no single specific marker to reliably distinguish ACC from other primary or metastatic neoplasms. However, a combination of immunohistochemical stains in a panel consisting of SRC-1, inhibin-α, calretinin, and HMWCK may be of aid in the differential diagnosis of these tumors. In addition, Pax8 is only rarely positive in ACC, which is a useful tool in their separation from renal neoplasms.
肾上腺皮质癌(ACC)是肾上腺皮质的罕见肿瘤,其临床病程侵袭性强。由于临床、形态学甚至免疫表型特征存在重叠,有时很难将这些肿瘤与其他肿瘤区分开来。为此,我们使用传统和新型标志物对40例ACC进行了全面的免疫组织化学分析。将由10种传统和新型抗体组成的免疫组织化学检测组合应用于ACC的全组织切片,包括高分子量细胞角蛋白(HMWCK)、低分子量细胞角蛋白(CAM5.2)、抑制素-α、黑色素A、嗜铬粒蛋白A、突触素、钙视网膜蛋白、类固醇受体辅激活因子-1(SRC-1)、配对盒基因8(Pax8)和Ki67。评估并记录阳性肿瘤细胞的百分比以及染色强度;对于Ki67,记录阳性肿瘤细胞的百分比。观察到SRC-1(39/40;97.5%)、抑制素-α(37/40;92.5%)、钙视网膜蛋白(32/40;80%)、突触素(29/40;72.5%)、黑色素A(26/40;65%)和CAM5.2(9/40;22.5%)呈阳性染色。罕见病例显示嗜铬粒蛋白A(2/40;5%)和Pax8(1/40;2.5%)呈阳性。所有病例均未显示与HMWCK有任何反应性。Ki67指数范围为<5%至20%。我们得出结论,没有单一的特异性标志物能够可靠地将ACC与其他原发性或转移性肿瘤区分开来。然而,由SRC-1、抑制素-α、钙视网膜蛋白和HMWCK组成的免疫组织化学染色组合可能有助于这些肿瘤的鉴别诊断。此外,Pax8在ACC中仅很少呈阳性,这是将其与肾肿瘤区分开来的有用工具。